Statement: There is no overlap between adverse events obeserved in the primary trial and the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 20/70 (28.57%)   NAUSEA 2/70 (2.86%)   VOMITING 1/70 (1.43%)   DIARRHOEA 2/70 (2.86%)   ABDOMINAL PAIN 1/70 (1.43%)   ABDOMINAL PAIN LOWER 1/70 (1.43%)   FATIGUE 2/70 (2.86%)   PYREXIA 1/70 (1.43%)   OEDEMA PERIPHERAL 1/70 (1.43%)   GENERAL PHYSICAL HEALTH DETERIORATION 3/70 (4.29%)   PNEUMONIA 1/70 (1.43%)   SINUSITIS 1/70 (1.43%)   LOBAR PNEUMONIA 1/70 (1.43%) Adverse Events 2:
Secondary_evidence: Adverse Events 1:   Total: 0/3 (0.00%)   Febrile Neutropenia * 0/3 (0.00%)   Neutropenia * 0/3 (0.00%)   Sudden Death * 0/3 (0.00%)   Bacterial Infection * 0/3 (0.00%)   Bronchitis * 0/3 (0.00%)   Sepsis * 0/3 (0.00%)   Lymphoedema * 0/3 (0.00%) Adverse Events 2:   Total: 6/41 (14.63%)   Febrile Neutropenia * 1/41 (2.44%)   Neutropenia * 1/41 (2.44%)   Sudden Death * 1/41 (2.44%)   Bacterial Infection * 1/41 (2.44%)   Bronchitis * 1/41 (2.44%)   Sepsis * 1/41 (2.44%)   Lymphoedema * 1/41 (2.44%)